Protagen

Protagen is a specialist in precision medicine and diagnostics, focusing on the identification of autoantibody signatures to support drug development and patient stratification. The company's proprietary SeroTag platform enables the systematic discovery of biomarkers for autoimmune diseases and immuno-oncology by profiling the humoral immune response. By identifying specific autoantibody patterns, Protagen helps pharmaceutical partners predict treatment response, monitor disease progression, and identify optimal patient cohorts for clinical trials. In March 2019, the company was acquired by Oncimmune Holdings to create a global leader in autoantibody-based diagnostics. The integration of Protagen's technology has significantly enhanced the combined entity's capabilities in personalized medicine across oncology and immunology.